Windlas Biotech — Peer Comparison

How the peer fair value is calculated and which companies were used as benchmarks.

Peer selection

Peers are selected from the same Branded generics & specialty pharma industry. 8 companies were matched as valid comparables.

Same-industry peers share similar business models, cost structures, and growth prospects — making them the most appropriate benchmarks for valuation multiples.

Peer comparison table

Branded generics & specialty pharma · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Windlas Biotech WINDLAS · you	₹2,320 Cr	34.1×	4.8×	—	14.1%	0.1%	—
Sector median	—	37.4×	3.8×	20.4×	12.5%	11.4%	14.7%
NATCO Pharma NATCOPHARM	₹15,503 Cr	11.0×	1.7×	10.9×	15.4%	34.8%	14.6%
Jubilant Pharmova JUBLPHARMA	₹15,442 Cr	38.2×	2.1×	15.3×	5.6%	4.8%	9.6%
Marksans Pharma Limited MARKSANS	₹13,495 Cr	32.9×	4.5×	20.7×	13.8%	14.2%	16.8%
CORONA Remedies Limited CORONA	₹12,727 Cr	64.4×	16.0×	46.6×	24.8%	13.2%	16.6%
Sanofi Consumer Healthcare India Limited SANOFICONR	₹10,285 Cr	45.5×	28.4×	31.4×	62.5%	27.3%	—
Strides Pharma Science Limited STAR	₹8,923 Cr	36.7×	2.5×	—	6.9%	0.1%	—
Medplus Health Services Limited MEDPLUS	₹7,968 Cr	45.5×	5.1×	12.1×	11.1%	3.2%	14.8%
Aarti Pharmalabs Limited AARTIPHARM	₹7,617 Cr	35.9×	3.0×	20.4×	8.2%	9.6%	-2.2%

Peer comparison verdict

Windlas is fairly valued relative to sector peers — trading near the sector median on key multiples (P/E ~37.4×, EV/EBITDA ~20.4×). Focus on execution quality and earnings trajectory from here.

How the peer fair value is calculated

Three valuation methods are weighted by sector. Each gives a fair value based on how sector peers are currently priced.

Method breakdown

40% weight · 8 peers

Sector median PE37.4×

Fair value via PE₹1,203

20% weight · 8 peers

Sector median PB3.8×

Fair value via PB₹856

EV/EBITDA

40% weight · 7 peers

Sector median EV/EBITDA20.4×

Fair value via EV/EBITDA—

Blended peer fair value₹1,088

Why median? Why these weights?

Median over mean: The sector median is used instead of the average because valuation multiples have extreme outliers — one high-growth company at 200× P/E would dramatically skew a mean. The median gives the middle value in the peer set, which better represents typical pricing.

Sector-specific weights: The weight given to each method reflects what matters most in this sector. For banks, P/B dominates because their value is tied to book assets. For IT companies, P/E carries the most weight because earnings quality matters more than asset base. For capital-intensive businesses, EV/EBITDA accounts for varying debt levels across peers and removes financing structure bias.

Limitations of peer comparison

Peer comparison assumes comparable companies are truly comparable — which is never perfectly true. Sector classifications can be imperfect: a conglomerate classified as "IT" may also have significant manufacturing revenue. Small peer counts (below 5) reduce confidence, as a single outlier can skew the sector median. When the entire sector is broadly expensive, peer comparison will show even an expensive stock as "fairly valued" relative to its peers.

The peer fair value shown is an algorithmic estimate based on publicly available financial data. It is not investment advice or a recommendation to buy, sell, or hold any security. Please consult a SEBI-registered investment adviser before making any investment decision.